Bolus Advisor with risk-based correction bolus, carbohydrate-free bolus recommender, and meal approval

Abstract

Basal and bolus recommendations are provided by analyzing the glycemic risk profile to determine whether basal or bolus amounts should be increased or decreased, taking into account the ratio of basal to bolus insulin as a fraction of total daily insulin. In some embodiments, the system and method seeks to correct systematic imbalances between fast acting bolus and daily basal, utilizing physiological cloning, which models the patient's diabetes data resulting from the patient's physiology and behavior (lifestyle and diet). In some embodiments, the system and method uses constraints on the percentage of total daily insulin attributable to basal and / or bolus. In some embodiments, the optimization is performed without using carbohydrate information provided by the patient.

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 129,919, filed December 23, 2020, entitled "BOLUS ADVISOR WITH CORRECTION BOLUSES BASED ON RISK, CARB-FREE BOLUS RECOMMENDER, AND MEAL ACKNOWLEDGEMENT," the contents of which are incorporated herein by reference in their entirety. [Background technology]

[0002] The availability and reliability of glucose time-series data has increased in recent years with the growing adoption of continuous glucose monitoring (CGM) systems and connected devices. However, despite the availability of reliable glucose data, accurate tracking of insulin and meal data, and effective timing of mealtime boluses of insulin, continues to be a problem for many people with diabetes, resulting in poor glucose control.

[0003] Traditional clinical advice suggests a fixed 50 / 50 basal / bolus insulin ratio, i.e., basal insulin should be half of the total daily insulin. Some more recent recommendations suggest 40 / 60, 30 / 70, or other ratios. However, a fixed percentage is not optimal for all patients. Previous efforts to provide treatment optimization by providing patients with basal and / or bolus recommendations have often suffered from inconsistent, incomplete, or inaccurate recommendations because the carbohydrate and / or exercise information collected / provided itself introduced imprecision into the data analysis.

[0004] It is with respect to these considerations and other considerations that the various aspects and embodiments of the present disclosure are presented. Summary of the Invention

[0005] The systems and methods described herein provide basal insulin recommendations (e.g., prescriptions) and bolus recommendations (e.g., prescriptions) by analyzing glycemic risk profiles to determine whether basal or bolus amounts should be increased or decreased, taking into account the ratio of basal insulin to bolus insulin as a fraction of total daily insulin. Bolus insulin refers to fast-acting insulin such as that used to meet insulin requirements at mealtimes or to correct transient hyperglycemia. In some embodiments, the systems and methods utilize physiological cloning, which models a patient's diabetes data derived from their physiology and behavior (lifestyle and diet), to attempt to correct systematic imbalances between fast-acting bolus and daily basal. In some embodiments, the systems and methods use constraints on the percentage of total daily insulin attributable to basal and / or bolus. In some embodiments, optimization is performed without using carbohydrate information provided by the patient.

[0006] Analysis of a patient's daily insulin pattern and glycemic risk ensures an optimal balance of basal insulin, bolus insulin, and / or total daily insulin while minimizing low and high glycemic risk. An insulin recommendation system is provided that adjusts basal and / or bolus percentages while reducing risk within a target range of basal / bolus ratios.

[0007] In one embodiment, a method includes assessing a glycemic risk based on a patient's glucose data, the glucose data including continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and the glycemic risk including at least one of high glycemic risk and low glycemic risk; quantifying a daily insulin relationship based on insulin data, the quantifying the daily insulin relationship based on the insulin data including calculating multiple aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, the insulin data including basal insulin data and bolus insulin data, the basal insulin data and bolus insulin data received for the patient over the period of time; determining a recommendation for one or more aspects of the patient's daily insulin based on a target range and the quantification of the glycemic risk and daily insulin relationship, the recommendation including a change in at least one of basal insulin, bolus insulin, and daily total insulin; and outputting the recommendation to a diabetes management system.

[0008] In one embodiment, the system includes at least one processor and a non-transitory computer readable medium that, when executed by the at least one processor, causes the system to assess glycemic risk based on glucose data of the patient, where the glucose data includes continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and where the glycemic risk includes at least one of high glycemic risk and low glycemic risk; and quantify a daily insulin relationship based on the insulin data, where quantifying the daily insulin relationship based on the insulin data includes assessing a glycemic risk for each day over the period of time. and comparing the calculated aspects over the period of time, wherein the insulin data includes basal insulin data and bolus insulin data, the basal insulin data and bolus insulin data received for the patient over the period of time; quantifying; determining a recommendation for one or more aspects of the patient's daily insulin based on the target range and the quantification of the glycemic risk and daily insulin relationship, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin; and outputting the recommendation to a diabetes management system.

[0009] In one embodiment, the system includes a glycemic risk assesser configured to assess glycemic risk based on glucose data of the patient, where the glucose data includes continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and the glycemic risk includes at least one of a high glycemic risk and a low glycemic risk; and an insulin relationship quantifier configured to quantify a daily insulin relationship based on the insulin data, where quantifying the daily insulin relationship based on the insulin data includes quantifying a daily insulin relationship for each day over the period of time. and an insulin recommender configured to determine a recommendation for one or more aspects of the patient's daily insulin based on the quantification of the target range and glycemic risk and daily insulin relationship, and output the recommendation to the diabetes management system, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin.

[0010] In one embodiment, a method includes identifying outlier data in a daily insulin-related pattern dataset, analyzing the outlier data in the daily insulin-related pattern dataset, removing the outlier data from the daily insulin-related pattern dataset, and communicating the removal of the outlier data to a diabetes management system.

[0011] In one embodiment, a system comprises at least one processor and a non-transitory computer-readable medium comprising instructions that, when executed by the at least one processor, cause the system to identify outlier data in a daily insulin-related pattern dataset, analyze the outlier data in the daily insulin-related pattern dataset, remove the outlier data from the daily insulin-related pattern dataset, and communicate the removal of the outlier data to a diabetes management system.

[0012] In one embodiment, the system includes an insulin relationship quantifier configured to identify outlier data in the daily insulin relationship pattern dataset, analyze the outlier data in the daily insulin relationship pattern dataset, and remove the outlier data from the daily insulin relationship pattern dataset, and an insulin recommender configured to communicate the removal of the outlier data to the diabetes management system.

[0013] In one embodiment, a method includes identifying variability in a daily insulin-related pattern dataset; analyzing the variability, including analyzing data that falls at least one of above a target range, within a target range, or below a target range; and making adjustments to the dataset based on the analyzing.

[0014] In one embodiment, the system comprises at least one processor and a non-transitory computer-readable medium comprising instructions that, when executed by the at least one processor, cause the system to: identify variability in a daily insulin-related pattern dataset; analyze the variability, where the variability includes analyzing data that falls at least one of above a target range, within a target range, or below a target range; and make adjustments to the dataset based on the analyzing.

[0015] In one embodiment, the system comprises at least one insulin-related quantifier or insulin recommender configured to identify variability in a daily insulin-related pattern dataset, analyze the variability, including analyzing data that falls at least one of above a target range, within a target range, or below a target range, and make adjustments to the dataset based on the analyzing.

[0016] This Summary introduces a selection of concepts in a simplified form that are further described below in the Detailed Description. As such, this Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.

[0017] The foregoing summary, as well as the following detailed description of exemplary embodiments, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the embodiments, there are shown in the drawings exemplary configurations of the embodiments. The embodiments are not limited to the specific methods and instrumentalities disclosed. The drawings are as follows: [Brief explanation of the drawings]

[0018] [Figure 1] FIG. 1 is a high-level functional block diagram of one embodiment of the present invention. [Figure 2] FIG. 1 is a system diagram of an embodiment of a bolus advisor. [Figure 3] FIG. 1 is a flow diagram of a method for determining daily insulin recommendations. [Figure 4] 1 is an example of a multi-graph representing CGM data, basal insulin data, and bolus insulin data received for a patient over a period of time. [Figure 5]An example of a CGM spaghetti graph found in clinical reporting software for CGM systems. [Figure 6] FIG. 6 is a graph showing risk profiles derived from the data of FIGS. 4 and 5, showing quantified assessments of glycemic risk for both high and low glycemic risk. [Figure 7] 7 is a graph showing an example of quantifying daily insulin relationship patterns, including a representation of bolus insulin (y-axis) versus basal insulin (x-axis), where the insulin relationship patterns are shown for the data sets of FIGS. 4-6 in one embodiment. [Figure 8] FIG. 7 is a graph showing another example of quantifying daily insulin relationship patterns, including a representation of the datasets of FIGS. 4-6 showing bolus insulin versus total daily insulin (TDI), where the insulin relationship patterns are shown for the datasets of FIGS. 4-6 in another embodiment. [Figure 9] 7A-7C are graphs showing another example of quantifying daily insulin relationship patterns, including representations of the datasets of Figures 4-6, with basal insulin versus TDI shown, where the insulin relationship patterns are shown for the datasets of Figures 4-6 in yet another embodiment. [Figure 10] FIG. 1 is a graph showing the expression of basal as a percentage of TDI for each day, where each day represents a day with sufficient data (excluding outliers) to determine a recommendation. [Figure 11] FIG. 10 is a flow diagram of a method for addressing outlier data in a daily insulin-related pattern dataset. [Figure 12] FIG. 12 is a graph of an example of outlier data for a patient in a daily insulin-related dataset, illustrating outlier data in the underlying dataset that, when analyzed, may represent inaccurate data (e.g., missing basal or bolus data) and / or erroneous data (inconsistent basal or bolus data). [Figure 13]FIG. 1 is a flow diagram of a method for addressing variability in daily insulin-related patterns. [Figure 14] 1 is a graph of an example of variability in insulin-related patterns throughout the day, where variability may be based on day of the week, etc. [Figure 15] 1 is a multigraph of an example of CGM data showing typical variability for a patient with type 1 diabetes. [Figure 16] For example, a graph showing both high and low glycemic risk because the profile exceeds a + / -1 threshold that can be used to identify risk, and / or both can be quantified and associated with a level of risk that may need to be addressed with basal and / or bolus adjustments. [Figure 17] 1 is a graph of an exemplary quantified daily insulin relationship. [Figure 18] 1 is an example graph showing a wide CI, indicating greater variability in the dataset. [Figure 19] 1 is a multi-graph of an example of CGM data variability for a patient with diabetes, with a consistent pattern of basal injections and typical variability in boluses. [Figure 20] 1 is a graph of a glycemic risk profile showing an example of unilateral low glycemic risk, particularly in the morning, which may be quantified as described in more detail herein. [Figure 21] Graph showing daily insulin relationship plotted as percent of TDI bolus, with daily insulin data well outside the target range. [Figure 22] 10 is a graph showing the daily insulin pattern confidence interval for percent basal, which is well above the target range. [Figure 23] 1 is a multi-graph of example data showing highly consistent adherence to a basal insulin regimen. [Figure 24] 1 is a graph of a glycemic risk profile identifying high risk above threshold 1. [Figure 25] 1 is a graph of an example of daily insulin relationship data plotted on a bolus vs. TDI graph, showing how the data points fall outside the bolus target range of 45%-55% of TDI. [Figure 26] 10 is a graph of an example providing recommendations to reduce the percentage of basal by increasing the amount of bolus for high glycemic. [Figure 27] 1 is a multigraph of an example where a patient has high glucose variability indicated by multiple glucose spikes near 400 mg / dL or at 40 mg / dL. [Figure 28] 1 is a graph of a glycemic risk profile identifying high glycemic risk above a predetermined threshold 1. [Figure 29] 1 is a graph of an exemplary quantified daily insulin relationship, plotting bolus as a percentage of TDI, with the bolus percentage being high and well outside the target range of 45-55%. [Figure 30] 1 is a graph showing that one data point (representing the daily insulin pattern for one day) is within the target range, but the confidence interval for the mean daily insulin basal percentage is clearly outside (i.e., below) the target range for TDI basal percentage. [Figure 31] 1 illustrates an exemplary computing environment in which exemplary embodiments and aspects may be implemented. DETAILED DESCRIPTION OF THE INVENTION

[0019] The claimed subject matter is described with reference to the drawings, wherein like reference numerals are used to refer to like elements throughout. In the following description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the claimed subject matter. It may be apparent, however, that the claimed subject matter may be practiced without these specific details. In other instances, structures and devices are shown in block diagram form to facilitate description of the claimed subject matter.

[0020] 1 is a high-level functional block diagram 100 of one embodiment of the present invention. A processor 130 communicates with an insulin device 110 and a glucose monitor 120. The insulin device 110 and the glucose monitor 120 communicate with a patient 140 to deliver insulin to the patient 140 and monitor the patient's 140 glucose level, respectively. The processor 130 is configured to perform calculations and other operations and functions described further herein. The insulin device 110 and the glucose monitor 120 may be implemented as separate devices, as a single device, within a single device, or across multiple devices. The processor 130 may be implemented locally in the insulin device 110, the glucose monitor 120, or as a standalone device (or in any combination of two or more of the insulin device 110, the glucose monitor 120, or the standalone device). The processor 130 or portions of the system may be located remotely, such as in a server or cloud-based system.

[0021] Examples of insulin devices, such as insulin device 110, include insulin syringes, external pumps, and patch pumps that deliver insulin to patients, typically subcutaneously. Insulin devices 110 also include devices that deliver insulin by different means, such as insulin inhalers, insulin jet injectors, intravenous infusion pumps, and implantable insulin pumps. An additional type of insulin device 110 is a smart insulin pen. In some embodiments, a patient uses two or more insulin delivery devices in combination, for example, injecting long-acting insulin with a syringe and using inhaled insulin before meals. In other embodiments, these devices can deliver other drugs that help control glucose levels, such as glucagon, pramlintide, or glucose-like peptide-1 (GLP1).

[0022] Examples of glucose monitors, such as glucose monitor 120, include continuous glucose monitors that record glucose values ​​at regular intervals, such as every 1, 5, or 10 minutes. These continuous glucose monitors can be, for example, transcutaneously inserted, fully implanted, or use electrochemical or optical sensors that noninvasively measure tissue. Examples of glucose monitors, such as glucose monitor 120, also include devices that periodically draw blood or other fluids to measure glucose, such as intravenous blood glucose monitors, microperfusion sampling, or periodic fingersticks. In some embodiments, glucose readings are provided in near real time. In other embodiments, glucose readings determined by the glucose monitor may be stored within the blood glucose monitor itself for subsequent retrieval. It is contemplated that various embodiments may be implemented in conjunction with or within a flash glucose monitor (FGM).

[0023] The insulin device 110, glucose monitor 120, and processor 130 can be implemented using a variety of computing devices, such as smartphones, desktop computers, laptop computers, and tablets. Other types of computing devices may also be supported. A suitable computing device is shown in FIG. 31 as computing device 3100 and cloud-based applications.

[0024] The insulin device 110, glucose monitor 120, and processor 130 may communicate over a network. The network may be a variety of network types, including a public switched telephone network (PSTN), a cellular network, and a packet-switched network (e.g., the Internet). Although only one insulin device 110, one glucose monitor 120, and one processor 130 are shown in FIG. 1 , there is no limit to the number of insulin devices, glucose monitors, and processors that may be carried. The activity monitor 150 and / or smartphone 160 may also be used to collect dietary and / or activity data from or about the patient 140 and provide the dietary and / or activity data to the processor 130.

[0025] Processor 130 may execute an operating system and one or more applications. The operating system may control which applications are executed by insulin device 110 and / or glucose monitor 120 and how the applications interact with one or more sensors, services, or other resources of insulin device 110 and / or glucose monitor 120.

[0026] The processor 130 may be configured and / or used to receive data from the insulin device 110 and the glucose monitor 120, and in some embodiments, from the patient 140, and to perform one or more of the calculations, operations, and / or functions further described herein.

[0027] 2 is a system diagram of an embodiment of bolus advisor 210. Inputs to bolus advisor 210 include blood glucose data 205 and insulin data 207. Blood glucose data 205 may be any diabetes data associated with a host, such as a human, and may include CGM-only data, BG (blood glucose) data, or other glucose or diabetes-related data, depending on the implementation. Insulin data 207 may be any insulin data associated with a host or human, depending on the implementation.

[0028] The bolus advisor 210 includes a glycemic risk evaluator 220, an insulin relationship quantifier 230, and an insulin recommender 240. The bolus advisor generates recommendations 250 and provides the recommendations 250 to the diabetes management system 280.

[0029] FIG. 3 is a flow diagram of a method 300 for determining a daily insulin recommendation.

[0030] At 310, glucose and insulin data are received for a patient. The system and method incorporate glucose and insulin data over a period of time to analyze daily insulin relationships and glycemic risk over a period of typical patient behavior. FIG. 4 is an example multigraph 400 depicting CGM data, basal insulin data, and bolus insulin data received for a patient over a period of time. The glucose and / or insulin data may, in some embodiments, be received from glucose monitor 120, patient 140, activity monitor 150, and / or smartphone 160. These data typically include glucose level measurements, including, for example, CGM readings, confidence readings assigned to CGM values, self-monitored blood glucose readings (glucose meters), and retrospectively calibrated or corrected CGM readings. The glucose data generally covers a selected period of at least one week.

[0031] The CGM graph 410 shows glucose time series data in mg / dL received over a period of approximately 60 days, the data being collected by a continuous glucose monitoring (CGM) system and representing blood glucose levels in a patient over that period.

[0032] The basal injection graph 420 shows the basal insulin time series data in units of insulin received over the same period, which data is collected by the smart insulin pen and represents the patient's basal insulin injections over time.

[0033] The bolus injection graph 430 shows the bolus insulin time series data in units of insulin received over the same period, which data is collected by the smart insulin pen and represents the bolus insulin injections in the patient over time.

[0034] It is contemplated that additional data types, including glucose and insulin data from other devices / systems, as well as additional data types such as exercise data and carbohydrate data, and other sensed input data and user-input data, may be collected. User-input data may include data based on meals and / or exercise and / or other activities. Meals and exercise and other activities may be explicitly ignored or disallowed in some embodiments. Additional inputs may include external process data, such as suggested basal rates and / or suggested bolus rates from an external process, which may include a pre-programmed basal profile (e.g., from an insulin pump), another artificial pancreas (AP) algorithm (e.g., an automated insulin delivery (AID) system), patient-initiated insulin delivery (basal or bolus), etc.

[0035] Some embodiments use or require continuous or semi-continuous data from a continuous glucose sensor, but not necessarily real-time. However, any glucose measurement that can be used to calculate glycemic risk as a function of time may be used. Retrospective or real-time data, smoothed or unsmoothed data may be used depending on the embodiment. Fingerstick data may be used in some embodiments, if comprehensive and preferably accompanied by carbohydrate data.

[0036] CGM data from free-living conditions is preferably used instead of collected fasting blood glucose (FBG) data. Free-living CGM data over time reflects the patient's lifestyle behaviors and actions. Conventional techniques use fasting blood glucose data, which is not a good measure for Type 1 patients with fluctuating daily activity, and FBG does not assist in decision-making for many active insulin management decisions and does not provide much insight into decision-making about fast-acting insulin or in balancing basal and bolus insulin.

[0037] The embodiment is used for basal / bolus / TDI optimization in intensively managed patients (patients taking bolus and basal insulin) as opposed to type 2 basal titration.

[0038] The received / selected CGM / insulin data must meet certain criteria.

[0039] The minimum data required for evaluation may include at least one day (or more), at least one week, or multiple weeks of CGM and insulin recordings, with multiple weeks providing more statistically significant data, which captures a broader range of behaviors.

[0040] Depending on how much data is available, further steps of this method can be adapted to achieve positive results all 24 hours a day.

[0041] Embodiments use data over a period of time sufficient to capture glucose data associated with a patient's typical lifestyle behaviors, i.e., glucose data associated with different behaviors and physiological experiences representative of a patient's typical lifestyle (e.g., weekends as opposed to weekdays, typical exercise days, sleep patterns, eating habits, etc.) There should be no changes in the treatment profile in the dataset.

[0042] Figure 5 is a CGM spaghetti graph 500 commonly found in clinical reporting software for CGM systems. This exemplary graph overlays multiple 24-hour daily glucose data for approximately 60 days of glucose from the CGM graph of Figure 4, visualizing glucose variability over each 24-hour period on consecutive days.

[0043] Because the data analysis of the systems and methods described herein is interested in daily insulin information, the start of the available data may not be the start of the 24-hour period that defines a day, and therefore a definition of the start of the first day and the start of the data set useful for analysis may be analyzed and determined.

[0044] It is contemplated that carbohydrate / meal information may not be required in some embodiments, although such information may be beneficial in some embodiments, particularly when variability and / or outlier data is being analyzed.

[0045] Outlier analysis (described further herein) may be performed as part of 310.

[0046] At 320, glycemic risk can be assessed based on the glucose data. Glycemic risk can include high glycemic risk and / or low glycemic risk, which can be a quantification of current and future risk of hyperglycemia and / or hypoglycemia, respectively. Glycemic risk can be calculated from blood glucose data and, in some embodiments, can be based on predicted glucose. In some embodiments, glycemic risk (e.g., calculated hypoglycemia and / or calculated hyperglycemia) uses predictions and / or state estimates. The glycemic risk assessor may be a blood glucose (BG) risk space quantification such as in low blood glucose index (LBGI) / high blood glucose index (HBGI) and / or examples and embodiments described in Patek-Actionable (U.S. Patent No. 10,638,981, entitled "METHOD, SYSTEM AND COMPUTER READABLE MEDIUM FOR ASSESSING ACTIONABLE GLYCEMIC RISK," inventor Stephen D. Patek, which is incorporated herein by reference in its entirety).

[0047] Risk may be assessed in terms of sample mean, sample variability, time in range, episodes of high / low BG, hypoglycemic risk, hyperglycemic risk, overall risk, and the like.

[0048] Any method for determining a patient's hypoglycemia and / or hyperglycemia level or risk profile may be utilized herein, as will be understood by those skilled in the art. Some known methods include U.S. Patent Application Publication No. 2020 / 0178905(A1) to Patek, which describes one method for assessing low glycemic risk, high glycemic risk, or both as a longitudinal profile. U.S. Patent Application Publication No. 2018 / 0366223(A1) to Kovatchev describes a method for calculating measures of hypoglycemia and hyperglycemia risk, where the hypoglycemic index (LBGI) is a non-negative quantity that increases with increasing number and / or severity of low BG readings, and the hyperglycemic index (HBGI) is a non-negative quantity that increases with increasing number and / or severity of high BG readings. U.S. Patent Application Publication No. 2016 / 0239622 A1 by Dunn et al. describes determining glycemic risk based on analysis of glucose data, including visualization of hypoglycemia, variability, and hyperglycemia, all of which are incorporated herein by reference in their entireties. An example of quantifying risk profiles can be found in U.S. Patent Application Publication No. 2020 / 0178905 A1, which is incorporated herein by reference in its entirety.

[0049] Figure 6 is a graph 600 illustrating a risk profile derived from the data of Figures 4 and 5, showing a quantified assessment of both high glycemic risk (above the 0 line) and low glycemic risk (below the 0 line). In this example, the patient does not have a high level of high or low glycemic risk because the values ​​are well below the + / - 1 threshold over a 24-hour day.

[0050] Glycemic risk can be quantitatively assessed to determine the individual risks of hyperglycemia and hypoglycemia and / or the relative risk of hyperglycemia versus hypoglycemia, for example, where there is an overall weighting toward hyperglycemia versus hypoglycemia (or vice versa). If the risk is unilateral, meaning much higher for hypoglycemia versus hyperglycemia (or vice versa), the relative importance of that risk is assessed and noted. Even if the risk is low overall and generally between hyperglycemia and hypoglycemia, recommendations can still be made based on quantified daily insulin relationship patterns, as discussed further herein.

[0051] In some embodiments, the risk assessment looks for a qualitative assessment (yes or no) of risk for hyperglycemia and / or hypoglycemia, e.g., whether the risk profile is outside the threshold and / or to what extent the risk remains outside the threshold.

[0052] In some embodiments, the assessment quantitatively assesses the amount of hyperglycemia and hypoglycemia overall and / or relative to one another.

[0053] The qualitative and / or quantitative assessment may be used to determine a recommendation, ie, whether and to what extent the basal and / or bolus should be adjusted.

[0054] At 330, the daily insulin relationship can be quantified based on the insulin data. In some embodiments, two or more aspects of daily insulin are calculated for each day over the period of available data. The insulin aspects include, for example, total daily insulin, total daily basal, and total daily bolus.

[0055] In some embodiments, relationship patterns can be identified by calculating at least two of the following aspects of insulin: total daily basal insulin (TDBasal), total daily bolus insulin (TDBolus), and total daily insulin (TDI) for each day over a series of days.

[0056] Two or more calculated aspects of insulin may be compared over a period of time to quantify the daily insulin relationship. A ratio or percentage of one aspect of insulin to another aspect of insulin over a period of time can be calculated. The relationship may be calculated daily, thereby forming daily relationship data. Each aspect may be compared on a daily basis, which may be kept as discrete data points and / or averaged over a period of time.

[0057] An average of each aspect of insulin may be calculated over a period of time, whereby the average insulin aspects may then be compared and a relationship pattern formed, for example, an average of each insulin aspect may be calculated and then the averaged insulin aspects compared.

[0058] The mean and standard deviation may be used to calculate a confidence interval, for example, the mean and standard deviation of the "bolus (or basal) percentage" (i.e., the percentage of TDI attributable to bolus (or basal)) over a period of time. A confidence interval may be determined for an estimate of the mean. If a patient has a consistent insulin delivery pattern from day to day, the confidence interval will be narrow (e.g., 95% of the confidence interval). If a patient is inconsistent, the confidence interval will be wider. Any variability in the pattern and / or outlier data may be addressed, as described further herein.

[0059] Depending on the implementation, other types of statistics may be used, such as medians or various percentiles. Each calculated insulin aspect may be plotted on a graph, for example, TDI vs. TDBasal, TDI vs. TDBolus, and / or TDBasal vs. TDBolus may be graphed as discrete data points over the day and / or as an average or mean with confidence intervals over the period of data collected / analyzed.

[0060] 7 is a graph 700 illustrating an example of quantifying the daily insulin relationship pattern, including a representation of bolus insulin (y-axis) versus basal insulin (x-axis), shown for the data sets of FIGS. 4-6 in one embodiment. The shaded cone 710 represents the 45-55% target range for the daily insulin relationship pattern.

[0061] Cluster 720 of data generally shows daily insulin trends that fall within or about 45-55% of the target range. Each dot in data cluster 720 represents a daily insulin-related data point for each individual day of the patient depicted in Figures 4-6. Each dot is a data point, with the x-axis value corresponding to how much basal insulin was injected per day and the y-axis value being how much bolus was injected per particular day.

[0062] The 95% confidence for the average basal (all days) and the 95% confidence for the average bolus are respectively represented by the vertically shaded region 730 and the horizontally shaded region 740. The area where regions 730, 740 intersect and fall within the shaded cone 710 represents a good basal-to-bolus ratio for the patient, approaching 50%.

[0063] The plus marks (shown on the y-axis and to the right of the cone) represent outliers and / or variability resulting from inaccurate or erroneous patient data represented in Figures 4-6, as described in more detail elsewhere herein (e.g., with respect to Figures 11 and 13).

[0064] A plus sign on the zero baseline (i.e., y-axis) corresponds to no reported basis on a day. A plus sign to the right of the cone likely corresponds to two basis on a day.

[0065] Outliers, whether due to inaccurate data on behavioral variability or other reasons, can be rejected as unknown.

[0066] FIG. 8 is a graph 800 illustrating another example of quantifying daily insulin relationship patterns, including a representation of the datasets of FIGS. 4-6 showing bolus insulin (y-axis) versus total daily insulin (TDI) (x-axis), where the insulin relationship patterns are shown for the datasets of FIGS. 4-6 in another embodiment.

[0067] The filled circles represent the daily insulin-related data for each individual day of the patients depicted in Figures 4-6.

[0068] The plus marks (shown on the left and right sides of cone 810) represent outliers and / or variability data resulting from inaccurate or erroneous patient data represented in Figures 4-6, as described in more detail elsewhere herein. y=0.5x is the center line of the target range (percentage of basal=50%).

[0069] The 95% confidence for the mean bolus and the 95% confidence for the mean TDI are respectively represented by the vertically shaded region 830 and the horizontally shaded region 840. The area where regions 830, 840 intersect and fall within the shaded cone 810 represents a good bolus to TDI ratio for the patient, close to 50 / 50 within the target range.

[0070] Cluster 820 of data generally shows daily insulin trends that fall within or about 45-55% of the target range.

[0071] In some embodiments, outlier data may be addressed as described in more detail elsewhere herein (eg, with respect to FIGS. 11 and 13).

[0072] In some embodiments, data outside a particular confidence interval (eg, 95%) may be ignored / removed for purposes of quantifying patterns and / or determining changes in insulin recommendations.

[0073] In this example, outlier and / or variability analysis was triggered because there were fewer than two rapid-acting boluses and / or the total amount of basal insulin deviated by more than 20% from the patient's prescription. Here, the three crosses above the cone 810 correspond to days where the recorded total daily insulin equaled the total daily insulin, signifying no basal insulin on those days. Whether this was due to an error in record-keeping or the patient chose not to take basal insulin on those days, the data from those days is removed or ignored to address misalignment in overall basal and bolus insulin. The two crosses where the total daily insulin exceeded 100 U correspond to days where the patient took substantially more basal insulin than prescribed and, furthermore, do not represent the patient's normal experience and are removed or ignored by the outlier and / or variability analysis.

[0074] FIG. 9 is a graph 900 illustrating another example of quantifying daily insulin relationship patterns, including a representation of the dataset of FIGS. 4-6 with basal insulin (y-axis) versus total daily insulin (TDI) (x-axis) shown, where the insulin relationship pattern is shown for the dataset of FIGS. 4-6 in yet another embodiment.

[0075] The filled circles represent the daily insulin-related data for each individual day of the patients depicted in Figures 4-6.

[0076] The plus marks (shown above cone 910 and on the x-axis) represent outliers and / or variability data resulting from inaccurate or erroneous patient data represented in Figures 4-6, as described in more detail elsewhere herein.

[0077] Clusters of data 920 generally show daily insulin trends that fall within or about 45-55% of the target range. 95% confidence for the average basal and 95% confidence for the average TDI are represented by vertically shaded region 930 and horizontally shaded region 940, respectively. The area where regions 930, 940 intersect and fall within shaded cone 910 represents a good bolus-to-TDI ratio for the patient, close to 50% within the target range.

[0078] Variability and / or outliers in the data may be addressed as described in more detail elsewhere herein (eg, with respect to Figures 11 and 13).

[0079] In this example, data from a given day was considered an outlier and / or unrepresentative if there were fewer than two rapid-acting boluses or if the total amount of basal insulin deviated by more than 20% from the patient's prescription. Here, three crosses on the basal = 0 line (i.e., the x-axis) correspond to days when the recorded total daily insulin equaled the total daily insulin, meaning there was no basal insulin on those days. Whether this was due to an error in recordkeeping or the patient chose not to take basal insulin on those days, data from those days should not be used to assess misalignment of total basal and bolus insulin. Two crosses with total daily insulin exceeding 100 U correspond to days when the patient took substantially more basal insulin than prescribed and are not representative of the patient's normal experience.

[0080] The groups of data above or below cone 910 may represent a superset of varying patterns, where data above cone 910 may represent, for example, when patients have different lifestyles (e.g., sporadic exercise).

[0081] In some embodiments, multiple daily insulin patterns may be identified, such as week patterns versus weekend patterns, as described in more detail elsewhere herein.

[0082] The data output from this step 330 can include the daily insulin relationship, one or more patterns of the daily insulin relationship, and the average daily insulin relationship, one or more patterns of the daily insulin relationship, outlier data, and / or variability data.

[0083] At 340, recommendations are determined for one or more aspects of daily insulin based on the glycemic risk assessment and the daily insulin relationship pattern quantification indicating whether basal or bolus should be increased, decreased, both, or neither.

[0084] Recommendations may be determined when the daily insulin pattern is outside of the target range, and the resulting recommendations (how to adjust basal / basal / TDI) may be based on glycemic risk.

[0085] In some embodiments, a recommendation may be considered when the daily insulin pattern is outside of the target range and is identified based on glycemic risk (whether to adjust basal / basal / TDI), with the recommendation being determined based on a quantitative or qualitative assessment of the amount the daily insulin pattern is out of range and the risk.

[0086] In some embodiments, a recommendation may be made when the daily insulin pattern is within the target range but the glycemic risk does not meet one or more criteria. For example, if high glycemic risk is present, increasing both the basal and bolus may be considered to reduce risk while maintaining the daily insulin profile within the target range.

[0087] The quantification of the daily insulin relationship pattern discussed above informs whether adjustments should be made to the daily insulin profile. That is, if the daily insulin relationship pattern is outside the target range, adjustments should be considered. For example, if the basal percentage is above the target range, the basal percentage should be reduced, and if the basal percentage is below the target range, the basal percentage should be increased.

[0088] The data output from 320 and / or 330 may be analyzed and compared to target ranges, which may be static or dynamic, may be patient-adaptive (e.g., based on patient settings or patterns), and / or may be day-dependent (e.g., weekends vs. weekdays).

[0089] The target range defines a range of acceptable values ​​for the daily insulin pattern data from 330, which assists in determining whether the daily insulin pattern is within an acceptable range and / or whether an increase or decrease in basal insulin, bolus insulin, and / or total daily insulin may be recommended.

[0090] Target ranges may be lifestyle-dependent, genetic, and / or diabetes stage-based, depending on the implementation. Target ranges may be arbitrary (e.g., selected by a clinician or patient, or set as a default), or may be based on a variability assessment or other analysis of patient data.

[0091] In contrast to prior art techniques that utilize fixed basal / bolus ratios for insulin optimization, the systems and methods described herein do not attempt to target a "one size fits all" approach, such as a fixed 50 / 50 or 40 / 60 ratio, for a patient. Rather, the determining step allows for a range of ratios that achieve good glycemic outcomes. In other words, the systems and methods described herein evaluate glucose data to determine whether a patient's daily insulin relationship is within a range of acceptable basal / bolus ratios that are appropriate to the patient's actual needs for improved glycemic control. Furthermore, the methods and systems described herein allow for adaptation of the target insulin ratio over time.

[0092] Daily insulin-related data that falls within the target range may not undergo any further analysis, and processing may proceed to an output step, and the patient may be notified that no changes are recommended at this time. However, processing may also continue with an adjustment decision based on the patient's glycemic profile. In other words, if the patient falls within the target range, but the patient's data indicates a risk of hypoglycemia or hyperglycemia above a predetermined threshold, the systems and methods described herein may continue to determine and recommend adjustments to daily insulin profiles that allow for a reduction in risk and maintain a daily insulin pattern within the target range.

[0093] In some situations, the basal / bolus is outside the target range, but no recommendation may be determined, for example, if the glycemic risk assessment indicates little or no glycemic risk (determined quantitatively and / or qualitatively as further described herein.) The systems and methods described herein may alternatively recommend smaller changes in basal and / or bolus when the target range is preferred, depending on the implementation, either by the software or the clinician utilizing the software.

[0094] The assessment of glycemic risk discussed above informs how adjustments should be made (to basal, to bolus, or to both), i.e., which daily aspects should be increased or decreased.

[0095] The systems and methods described herein are guided by glycemic risk to determine whether the basal should be adjusted, the bolus should be adjusted, or both, with or without a change in TDI.

[0096] Daily insulin-related data outside the target ranges are subject to adjustment decisions based on the patient's glycemic risk profile, i.e., the recommendation to increase and / or decrease any one or more daily insulin aspects is based on an analysis of high and / or low glycemic risk determined by or in accordance with the patient's glucose data, depending on the embodiment.

[0097] For example, if the glycemic risk is low overall but the percentage of basal should be increased, but the glycemic risk is generally even between hyperglycemia and hypoglycemia, both the increase to basal and the decrease to bolus together increase the percentage of basal. In this case, because the risk is not one-sided, the recommendation hits both basal and bolus but has the net effect of increasing the percentage of basal.

[0098] The glycemic risk assessment and / or daily insulin quantification may further determine how much adjustment should be made, e.g., a 5% increase for basal, a 5% decrease for bolus, etc. As will be appreciated by one of skill in the art, the actual amount of insulin may be in units or calculated.

[0099] Some exemplary recommendations include, but are not limited to:

[0100] If the daily insulin pattern is above the target range, the determined adjustments may include an increase in the daily basal, a decrease in the daily bolus, or both, depending on the patient's glycemic risk profile.

[0101] If the daily insulin pattern is below the target range, the adjustments determined may include increasing the daily basal, decreasing the daily bolus, or both, depending on the patient's glycemic risk profile.

[0102] If the daily insulin pattern is not clearly within or outside the range, for example, if the confidence interval for the pattern is within / above half of the upper limit of the target range, which indicates a tendency for having too many boluses but is not significant enough to recommend a change, some embodiments may assess glycemic risk, message the patient, and / or provide feedback to address outliers and / or variability in the data, as described in more detail elsewhere herein (e.g., with respect to Figures 11 and 13).

[0103] In some cases, if the daily insulin pattern is outside the target range but the glycemic risk profile is within the threshold, no recommendation may be determined and / or the system may determine an adaptive target range for the patient and / or query the patient for a daily insulin pattern and a custom target range.

[0104] In some cases, if the daily insulin pattern is within the target range but the glycemic risk profile is outside the threshold, there may be a problem with the patient's prescription, but the problem is not actually a problem of basal / bolus misalignment. In such cases, we recommend consulting with the patient's physician or other healthcare professional to discuss any out-of-range glycemic data (e.g., significant hyperglycemia / hypoglycemia) other than the basal to bolus insulin ratio.

[0105] In some embodiments, the systems, methods, and / or logic described herein either increase the basal or decrease the bolus, or vice versa, in situations where the glycemic risk is clearly one-sided (where the risk on one side is either hypoglycemia or hyperglycemia, but not both). Alternatively, when hyperglycemia and hypoglycemia are evenly matched, the systems, methods, and / or logic adjust both (e.g., increase or decrease the basal or bolus depending on whether one needs to be increased or decreased).

[0106] Any adjustments (increases or decreases) to one or more aspects of daily insulin (TDBasal, TDBoI, TDI) can be determined by glycemic risk and daily insulin relationship patterns (i.e., relative to target ranges). In other words, if glucose data indicate glycemic risk above / below a predetermined threshold, adjustments can be simulated for one or more percentage increases / decreases in one or more aspects of daily insulin, using the midpoint, outer boundary, or any region of the range as the adjustment target, as would be understood by one of skill in the art. Additionally, the selected adjustments can be percentage increases / decreases informed by the target ranges, set points, and / or any other data available from the patient (e.g., patient lifestyle, outliers, patient data variability, relative risk tolerance, etc.), as described above.

[0107] The following guidelines may be followed if the daily insulin pattern falls outside the target range, although other guidelines may be useful as well, depending on the embodiment and / or situation.

[0108] If hyperglycemia risk is above the threshold and the daily insulin pattern is above the target range, the percentage of TDI is increased from basal.

[0109] If the hypoglycemia risk is above the threshold and the daily insulin pattern is above the target range, the percentage of TDI is reduced from the bolus.

[0110] If hyperglycemia risk is above the threshold and the daily insulin pattern is below the target range, the percentage of TDI is reduced from basal.

[0111] If hypoglycemia risk is above threshold and the daily insulin pattern is below the target range, the percentage of TDI is increased from bolus.

[0112] If hypoglycemic risk is present without hyperglycemic risk, or vice versa, the TDI may be decreased or increased, respectively.

[0113] The TDI change may be alone or in combination with the basal / bolus change.

[0114] In some cases, where the increase or decrease applies to only certain aspects of the daily insulin, the TDI may be increased or decreased accordingly, respectively. In some cases, the TDI is determined to be adjusted.

[0115] In some embodiments, the TDI may be changed while changing the basal / bolus ratio, although limits on allowable TDI change may apply.

[0116] If the TDI is outside the acceptable change limits, the determined adjustment may be reevaluated for further adjustment of other aspects of the daily insulin until additional criteria are met, such as criteria for glycemic risk, criteria for daily insulin pattern, and acceptable TDI, physician-recommended basal insulin range, specific criteria associated with available units of insulin (e.g., rounding to whole numbers), restrictions associated with the method of administration, etc.

[0117] In some cases, the combination of (i) decreasing the basal and (ii) increasing the bolus may be determined based on, for example, the risk of hyperglycemia versus the risk of hypoglycemia.

[0118] The TDI may be varied and the system and method may identify, for example, a 25th to 75th percentile range and flag situations where a patient is experiencing / reporting an abnormal amount of total insulin in a day.

[0119] In some situations, the dataset and associated daily insulin pattern may not be consistent enough to accurately determine adjustments using the systems and methods described herein without additional insight into the patient's daily behavioral patterns. This can occur for a variety of reasons, such as differences in daily needs / activity / behavior / eating behavior. For example, the TDI or total daily basal (TDB) requirement may not be the same from day to day. Sometimes, patient data may be highly variable or even erroneous. In these cases, addressing outlier data and / or variability in the data may be performed before, in combination with, after, or iteratively during the feedback look with adjustment decisions.

[0120] FIG. 10 is a graph 1000 showing a representation of basal as a percentage of TDI (y-axis) for each day (x-axis), where each day represents a day with sufficient data (excluding outliers) to determine a recommendation. The shaded band 1010 represents 45-55% of the target range for basal as a percentage of TDI. The x-axis is the number of days (not necessarily consecutive, but all days where the percentage of basal data values ​​and the percentage of bolus data values ​​were complete and not out of range) for which there was sufficient quality data for the days used in the calculation.

[0121] The star 1020 is a data point representing basal as a percentage of daily TDI. The star 1020 has a mean value that is exactly in the middle of a dotted rectangular band 1030, and the 95% CI is the confidence level that the mean value falls within that band.

[0122] The dotted rectangular band 1030 in the middle of the target range is a 95% confidence interval for the estimate of the mean value of the data points; the band is narrow and well within the target range. In this example, the very narrow band that falls within the target range indicates that the actual mean basal percentage is very close (with 95% confidence) to the sample mean. This also indicates that the basal percentage has very little day-to-day variation, here very close to 50% basal of the TDI, which means that 95% of the time, it is very close to that range of values ​​for the basal percentage of the TDI for that day. This illustrates a patient under good control with a good 50 / 50 basal-bolus ratio.

[0123] This is an example of someone who may not need the recommended adjustments in their daily insulin. Further examples, described in more detail elsewhere herein, illustrate other scenarios of typical patients with diabetes who would benefit from the systems and methods described herein for adjusting basal and / or bolus values ​​daily.

[0124] At 350, a recommendation (or recommendations) is output to the diabetes management system. The recommendation may be in the form of a report, a command, or a signal or instruction to an insulin delivery system, a therapy optimization algorithm, etc. Additionally, or alternatively, the recommendation may be provided to the patient, a physician or other medical professional, an administrator, or any device, system, and / or algorithm that manages diabetes. In some embodiments, a message may be sent to the patient, physician, medical professional, administrator, etc. regarding any outlier data, variability in the data, a determined recommendation with a query or observation, making a recommendation (e.g., regarding variability) with or without additional context, feedback prompting to re-run the algorithm, etc.

[0125] In some embodiments, the determined adjustment (eg, a numerical adjustment or recommendation) is rounded to an integer value or other applicable unit.

[0126] When output to the insulin delivery system, the determined bolus adjustment may be implemented, for example, by proportionally varying the carbohydrate ratio and / or correction factor.

[0127] Another embodiment of the determined adjustment may be to increase or decrease the basal and / or bolus by a percentage rather than a specific amount, such as a 10% increase or decrease.

[0128] Determined recommendations may be output along with messaging to adjust insulin requirements to environmental or behavioral consistency, for example, regarding exercise behavior or dietary patterns.

[0129] In some cases, no change is recommended, but patients are messaged about their significant risk of hyperglycemia and / or hypoglycemia despite achieving a reasonable balance between basal and bolus insulin, and consultation with their physician is recommended to consider other sources of out-of-range blood glucose.

[0130] It is contemplated that the systems, methods, and / or algorithms described herein may be implemented as modules of an open-loop therapy titration algorithm or system.

[0131] FIG. 11 is a flow diagram for a method 1100 for addressing outlier data in a daily insulin-related pattern dataset. In some situations, the dataset and associated daily insulin pattern may be distorted by outlier data, e.g., missing or erroneous patient data. Examples of compromised data integrity include failure to record (or timely record) basal and / or bolus events, perhaps resulting from a technical malfunction in a “connected” insulin pen or insulin pump. Examples of outlier activity include running a marathon and mountain climbing, where a patient may intentionally deviate significantly from their prescribed basal insulin for one or more days. Outlier addressing may be performed before, during, and / or after any of the method steps described herein, for example, as a data scrubbing step and / or validation step, and / or as a feedback loop within one or more steps of the method.

[0132] At 1110, outlier data is identified in the daily insulin-related pattern dataset, which may be inaccurate or may include erroneous data points. Outlier data includes inaccurate or erroneous data that distorts the pattern analysis, which may result in an inaccurate insulin adjustment recommendation. It is contemplated that there may be some cases where there are numerous outliers and where non-outliers represent such a wide range of daily percentage-basal that an equalization recommendation cannot be made despite glycemic risk.

[0133] Inaccurate data includes missing data and / or incorrectly labeled data. Inaccurate data, including any data in the underlying dataset used to identify, includes missing data (no bolus insulin reported for the day), improperly time-stamped data, or otherwise corrupted or faulty data, empty fields, zero values, etc. Examples include a patient forgetting to enter bolus information and / or data that is not properly transferred from the insulin delivery device to the software that runs the daily insulin relationship assessment algorithm.

[0134] In the exemplary use case of an MDI (multiple injections per day) patient using two different insulin pens for basal and bolus insulin delivery, synchronized and / or manual data entry of delivered basal and bolus amounts may be subject to user-driven or technology-related errors.

[0135] Erroneous data includes data that may be accurate but result from outlier behavior in eating or activity patterns. Data may be anomalies or may be driven by outlier behavior. Examples of outlier behavior include fasting and overeating, running out of insulin, running a marathon, and other prolonged situations that distort daily pattern analysis.

[0136] Identifying outlier data includes identifying any inaccurate or erroneous data as described above or as would be understood by one of ordinary skill in the art.

[0137] At 1120, the outlier data is analyzed. Analyzing the outlier data in the daily insulin relationship pattern includes analyzing the data set underlying the analysis to determine whether there is enough good data to make recommendations and / or determine adjustments.

[0138] In this way, a consistent pattern in the basal-to-bolus ratio can be ensured. Without a consistent pattern, adjustment decisions may be inaccurate or inappropriate.

[0139] Generally speaking, any day where the basal percentage is below a predetermined threshold or above another predetermined threshold is likely a day where either (i) information about insulin delivery is missing or (ii) there is something unrepresentative about that day (e.g., the patient ran out of basal insulin, ran a marathon, etc.).

[0140] Analyzing outlier data can be as simple as ignoring or removing data from a dataset where no basal or bolus doses are present. The analysis of daily insulin patterns of the systems and methods described herein, in some embodiments, includes an analysis of at least two of the daily insulin aspects described further herein. The data associated with those at least two of the daily insulin aspects includes a complete dataset for both basal and bolus (and thus total daily insulin). In the absence of daily data for basal or bolus, the systems and methods described herein may output inaccurate recommendations.

[0141] In some embodiments, the data sets are analyzed for statistical consistency to ensure that consistent patterns can be obtained.

[0142] In some embodiments, the systems and methods analyze the dataset for a minimum number of days that meet a consistency threshold, ensuring that the actual ratio calculated for that day is within some reasonably broad range of possible ratios (e.g., anywhere from 10% to 90%) and / or that a certain number of days meets the criteria.

[0143] The analysis can assess day-to-day consistency and / or variability, e.g., statistical deviation bounded by a threshold, for example, if the ratio has a 95% confidence interval wider than the acceptable range for the TDI.

[0144] In some embodiments, daily TDB and TDI values ​​are collected from historical records and non-compliant days are omitted.

[0145] In some embodiments, at least one week of CGM data is used to determine the pattern.

[0146] 12 is a graph 1200 of an example of outlier data for a patient in a daily insulin-related dataset illustrating outlier data in the underlying dataset, which, when analyzed, may represent inaccurate data (e.g., missing basal or bolus data) and / or erroneous data (inconsistent basal or bolus data). In this case, there are several days where the basal insulin is twice the median basal value, and there are corresponding days where the basal insulin is 0. This may reflect a situation where a patient slows down in taking their basal insulin on a given day (creating a 0 basal day) and then taking additional regularly prescribed basal doses at the usual time (creating 2 x basal days). In some embodiments, these types of days may be removed or ignored by the systems and methods described herein.

[0147] At 1130, outlier data is removed from the daily insulin relationship pattern dataset. In some embodiments, the TDI is evaluated across a range of data to determine whether the data is within a predetermined range. The TDI range from the dataset can be used to limit the TDI range for an adjustment determination method step using the identification (and removal) of outliers from the dataset.

[0148] At 1140 (optional), information related to the outlier data removed from the daily insulin-related pattern dataset is output (e.g., to the patient, physician, administrator, storage device, report, etc.). The removal of the outlier data may be communicated to a diabetes management system and / or fed back to one or more of the methods described herein. In some embodiments, the patient and / or physician may be notified (e.g., by message) to determine the underlying cause or to verify the accuracy or representation of the data.

[0149] 13 is a flow diagram of a method 1300 for addressing variability in daily insulin-related patterns. The process of addressing variability may be triggered when the data falls outside one or more predetermined criteria, for example, by comparing the quantified insulin-related pattern data to a target range. Criteria include whether and / or how much of the data is above, within, and / or below the target range.

[0150] In one example, if the 95% confidence interval for the mean completely encompasses the target range, there will be reliable days above the range and reliable days below the range. In this case, instead of just saying "not clearly out of range," the indicator might say something like "there is no clear pattern to your basal / bolus mix." Figure 17 is a graph 1700 of an example of this (e.g., an exemplary quantified daily insulin relationship).

[0151] In some circumstances, the data set and associated daily insulin pattern may be a superset of two or more subsets of patterns associated with data variability, e.g., patient data that varies over time.

[0152] Addressing data variability may be performed before, during, and / or after any of the steps of method 300 of FIG. 3 and / or method 1100 of FIG. 11, for example, as a feedback loop (e.g., sending a subset back to a decision step within one or more steps of the method).

[0153] At 1310, variability in the daily insulin-related pattern dataset is determined.

[0154] In some embodiments, more than one pattern may be represented by the data set. In general, there may not be a single consistent or systematic adjustment / decision to make. Additionally, or alternatively, there are no real adjustments to make when the patient is already self-regulating for these behavioral differences.

[0155] Variability in patterns can result from wide confidence intervals (outside thresholds) and different analyses of time periods, days of the week definitions, etc. can result in multiple different patterns.

[0156] Variability can be determined, for example, by analyzing individual data points and / or assessing the mean and / or standard deviation against one or more criteria.

[0157] The process of identifying variability may include evaluating a superset of data, a data set described elsewhere herein, to identify one or more subsets of data associated with different daily insulin patterns.

[0158] Variability in the daily insulin-related pattern dataset is analyzed at 1320. The process of analyzing the data can include analyzing data above, within, and / or below the target range.

[0159] 14 is a graph 1400 of an example of variability in insulin-related patterns throughout the day, where the variability may be based on day of the week, etc. For example, patients may have different lifestyles (e.g., night shift work, alternating exercise patterns, overeating on weekends, etc.) and require different solutions.

[0160] System and / or method implementations may query the patient and / or find ways to derive a subset of patterns and / or analyze additional diet or activity related data, if available.

[0161] Analyzing the variability of the daily insulin relationship pattern includes analyzing the data set underlying the analysis to determine whether there is enough good data to make a recommendation and / or to determine adjusted basal and / or bolus recommendations for the entire data set.

[0162] In some situations, the data sets and associated daily insulin patterns may not be consistent enough to be accurately assessed using the systems and methods described herein without additional insight into the patient's daily behavioral patterns, which can occur for a variety of reasons, such as differences in daily needs / activity / behavior / eating behavior. For example, the TDI or total daily basal (TDB) requirement may not be the same from day to day. Sometimes patient data is highly variable due to normal or abnormal behavioral patterns.

[0163] At 1330, adjustments are made based on the analyzed variability in the daily insulin-related pattern dataset. Adjusting may include adjusting the definition of the data (e.g., start / end of a 24-hour period), which may include different sleep patterns, working patterns (e.g., night shift), and / or splitting the data into two or more separate datasets / patterns (e.g., weekdays vs. weekends).

[0164] Thus, the systems and methods described herein allow for adaptation of the TDI and / or basal / bolus ratio over time. These techniques are used in some embodiments when the TDI across the range of data is within a reasonable range. Processes can be implemented that attempt to make this adaptation, such as by changing the definition of days and / or performing a moving average.

[0165] A TDI with daily ratios can be calculated. Outliers can be removed in a feedback loop. The definition of a day can be changed in a feedback loop and can be based on CGM traces. Using multiple TDIs with daily ratios, these can be provided as continuous, average, or moving average. In some embodiments, weekdays can be distinguished from weekends (or weekdays vs. holidays). In some embodiments, the end of a day can be defined.

[0166] Next, examples will be described.

[0167] Example 1: This example illustrates a situation where (i) historical data for a patient indicates some exposure to hypoglycemia risk and hyperglycemia risk, but (ii) the basal insulin to total daily insulin ratio is not clearly outside the range of 45%-55%, ultimately resulting in a "no change" recommendation.

[0168] Figure 15 is a multigraph 1500 of an example of CGM data showing typical variability for a patient with type 1 diabetes. The CGM data shows typical variability for a patient with type 1 diabetes. Basal injections are generally consistent except for day 15, which triggers outlier analysis (removal) prior to assessing glycemic risk based on the data. It is also notable that the bolus pattern is fairly sporadic, but not unusual for patients with type 1 diabetes who have a variety of lifestyles.

[0169] FIG. 16 is a graph 1600 showing both high and low glycemic risk, for example, for profiles to exceed a + / -1 threshold that can be used to identify risk, and / or both can be quantified and associated with a level of risk that may need to be addressed with basal and / or bolus adjustments.

[0170] 17 is an exemplary graph 1700 of the quantified daily insulin relationship. However, there are so many outliers and so much variability in the data that it can be unclear how to make recommendations. It appears that at least some of the outliers occurred because basal values ​​were either not reported or perhaps taken late / early and counted on different days.

[0171] 18 is an example graph 1800 showing a wide CI (e.g., compared to FIG. 10), indicating greater variability in the dataset. CI zone 1810 falls at least partially within target range zone 1820, and thus the average estimate of the daily insulin pattern may fall within the target range. Additionally, in this exemplary dataset, there are numerous outliers, as well as non-outliers, indicating a very wide range of daily basal percentages, such that no insulin recommendation is determined here, despite the presence of some glycemic risk.

[0172] Example 2: This example illustrates a situation where (i) historical data for a patient indicates significant exposure to hypoglycemia risk, and (ii) the ratio of basal insulin to total daily insulin is significantly above the 45%-55% range (equivalently, the ratio of bolus insulin to total daily insulin is significantly below the 45%-55% range). Although the insulin ratio can be normalized by either decreasing basal insulin or increasing bolus insulin (or both), due to the hypoglycemia risk, the system / method / apparatus herein chooses to decrease basal insulin, thereby decreasing total daily insulin.

[0173] 19 is an example multigraph 1900 of CGM data variability for a patient with diabetes who has a consistent pattern of basal injections and typical variability in boluses. Compared to Example 1, FIG. 19 shows some variability in daily basal insulin doses. Under more extreme variability in daily basal doses, an example output to a diabetes management system may recommend that the patient be more consistent in their basal / bolus behavioral strategy and / or in reporting consistency to utilize a recommender.

[0174] FIG. 20 is a graph 2000 of a glycemic risk profile showing an example of low glycemic risk, particularly on one side in the morning, which may be quantified as described in more detail elsewhere herein.

[0175] 21 is a graph 2100 showing the daily insulin relationship plotted as a percentage of the TDI bolus, with the daily insulin data being significantly outside the target range. Specifically, the bolus percentage is consistently lower than expected (relative to the target range).

[0176] 22 is a graph 2200 showing the daily insulin pattern confidence interval for basal percentage, which is well above the target range 2210. In this example dataset, the system and method determines a recommendation to reduce the basal percentage by decreasing the amount of basal based on unilateral hypoglycemia risk assessed by risk profiling (FIG. 20) and the quantified daily insulin pattern (FIG. 21).

[0177] An exemplary output to a diabetes management system may include a specific amount, such as "reduce basal by 10%."

[0178] Example 3: This example illustrates a situation where (i) historical data for a patient indicates significant exposure to hyperglycemia risk, and (ii) the ratio of basal insulin to total daily insulin is significantly above the 45%-55% range (equivalently, the ratio of bolus insulin to total daily insulin is significantly below the 45%-55% range). While the insulin ratio can be normalized by either decreasing basal insulin or increasing bolus insulin (or both), due to the risk of hyperglycemia, the system / method / apparatus herein chooses to increase bolus insulin, thereby increasing total daily insulin.

[0179] FIG. 23 is a multigraph 2300 of an example of data showing very consistent adherence to the basal insulin regimen, except for the week after day 7 after experiencing severe hypoglycemia, when the patient may have decided to taper off the basal insulin to avoid a recurring occurrence.

[0180] Figure 24 is a graph 2400 of a glycemic risk profile identifying high glycemic risk above Threshold 1. The data shows that patients, sometimes referred to as "low fear" individuals, consistently manage their insulin to avoid hypoglycemia.

[0181] FIG. 25 is an example graph 2500 of daily insulin relationship data plotted on a bolus versus TDI graph showing how the data points fall outside the 45%-55% TDI bolus target range.

[0182] 26 is a graph 2600 of an example providing a recommendation to decrease the percentage of basal by increasing the amount of bolus due to hyperglycemia. If hyperglycemia is an assessed risk (one sided), more insulin is needed in the patient's system and the daily insulin pattern indicated an excessively high basal, so the logic of the system / method is designed to increase insulin, for example, by increasing the bolus, and decrease the percentage of basal.

[0183] An example output to the diabetes management system may be to increase all boluses (except basal boluses) by 10%, or to program parameter changes to carbohydrate ratios and / or correction factors that output increased boluses from the bolus calculator used for mealtimes and / or corrections.

[0184] Example 4: This example illustrates a situation where (i) historical data for a patient indicates significant exposure to hyperglycemia risk, and (ii) the ratio of basal insulin to total daily insulin is significantly below the 45%-55% range (equivalently, the ratio of bolus insulin to total daily insulin is significantly above the 45%-55% range). Although the insulin ratio could be normalized by either increasing basal insulin or decreasing bolus insulin (or both), due to the risk of hyperglycemia, the system / method / apparatus herein chooses to increase basal insulin, thereby increasing total daily insulin.

[0185] 27 is a multigraph 2700 of an example where a patient has high glucose variability indicated by numerous glucose spikes near or at 400 mg / dL. The patient appears to be taking approximately 23 units of basal insulin once a day quite consistently, and the insulin fluctuations throughout the day can be attributed to bolus insulin delivery.

[0186] Figure 28 is a graph 2800 of a glycemic risk profile that identifies a high glycemic risk above a predetermined threshold of 1 (here, even above 2). When hyperglycemia risk is quantified, for example, the area under the curve (shading 2810) of all values ​​above 0 that correlate with glucose above the threshold shows that the risk assessment is highly correlated with hyperglycemia risk. Amounts above the hyperglycemia glucose threshold are clearly greater than amounts below the hypoglycemia threshold, indicating a heavier weighting for hyperglycemia risk. None of the hypoglycemia risk profiles are outside of threshold 1. The problems this patient is experiencing are related to hyperglycemia, not hypoglycemia.

[0187] 29 is a graph 2900 of an exemplary quantified daily insulin relationship, plotting bolus as a percentage of TDI, where the bolus percentage is high and well outside the 45-55% target range. Then, by inference, the basal as a percentage of TDI insulin is expressed as too low and outside the 45-55% target range.

[0188] 30 is a graph 3000 showing that one data point (representing the daily insulin pattern for a given day) is within the target range, but the confidence interval for the mean daily basal insulin percentage is clearly outside (i.e., below) the target range represented by the shaded area for the TDI basal percentage 3010. In this exemplary data set, the systems and methods described herein determine a recommendation to increase the basal percentage by increasing the basal amount based on the high glycemic risk identified in FIG. 28 and the daily insulin relationship pattern identified in FIG. 29.

[0189] Exemplary outputs to a diabetes management system may include a numerical recommendation such as "Increase your daily basal by 10%" or a qualitative recommendation such as "Increase your basal; see your doctor for detailed guidelines."

[0190] 31 illustrates an exemplary computing environment in which exemplary embodiments and aspects may be implemented. The computing device environment is only one example of a suitable computing environment and is not intended to suggest any limitation as to the scope of use or functionality.

[0191] Numerous other general purpose or special purpose computing device environments or configurations may also be used. Examples of well-known computing devices, environments, and / or configurations that may be suitable for use include, but are not limited to, personal computers, server computers, handheld or laptop devices, multiprocessor systems, microprocessor-based systems, networked personal computers (PCs), minicomputers, mainframe computers, embedded systems, distributed computing environments that include any of the above systems or devices, etc.

[0192] Computer-executable instructions, such as program modules, executed by a computer may be used. Generally, program modules include routines, programs, objects, components, data structures, etc. that perform particular tasks or implement particular abstract data types. Distributed computing environments may be used in which tasks are performed by remote processing devices that are linked through a communications network or other data transmission medium. In a distributed computing environment, program modules and other data may be located in both local and remote computer storage media, including memory storage devices.

[0193] 31 , an exemplary system for implementing aspects described herein includes a computing device, such as computing device 3100. In its most basic configuration, computing device 3100 typically includes at least one processing unit 3102 and memory 3104. Depending on the exact configuration and type of computing device, memory 3104 may be volatile (such as random access memory (RAM)), non-volatile (such as read-only memory (ROM), flash memory), or some combination of the two. This most basic configuration is indicated in FIG. 31 by dashed line 3106.

[0194] Computing device 3100 may have additional features / functionality. For example, computing device 3100 may include additional storage (removable and / or non-removable) including, but not limited to, magnetic or optical disks or tape. Such additional storage is illustrated in FIG. 31 by removable storage 3108 and non-removable storage 3110.

[0195] Computing device 3100 typically includes a variety of computer-readable media, which can be any available media that can be accessed by device 3100 and includes both volatile and nonvolatile media, removable and non-removable media.

[0196] Computer storage media includes volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer-readable instructions, data structures, program modules, or other data. Memory 3104, removable storage 3108, and non-removable storage 3110 are all examples of computer storage media. Computer storage media include, but are not limited to, RAM, ROM, electrically erasable program read-only memory (EEPROM), flash memory or other memory technology, CD-ROM, digital versatile disk (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium that can be used to store the desired information and that can be accessed by computing device 3100. Any such computer storage media may be part of computing device 3100.

[0197] Computing device 3100 may contain communications connections 3112 that allow the device to communicate with other devices. Computing device 3100 may also have input devices 3114, such as a keyboard, mouse, pen, voice input device, touch input device, etc. Output devices 3116, such as a display, speakers, printer, etc. All of these devices are well known in the art and need not be discussed at length here.

[0198] In one embodiment, a method includes assessing a glycemic risk based on a patient's glucose data, the glucose data including continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and the glycemic risk including at least one of high glycemic risk and low glycemic risk; quantifying a daily insulin relationship based on insulin data, the quantifying the daily insulin relationship based on the insulin data including calculating multiple aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, the insulin data including basal insulin data and bolus insulin data, the basal insulin data and bolus insulin data received for the patient over the period of time; determining a recommendation for one or more aspects of the patient's daily insulin based on a target range and the quantification of the glycemic risk and daily insulin relationship, the recommendation including a change in at least one of basal insulin, bolus insulin, and daily total insulin; and outputting the recommendation to a diabetes management system.

[0199] Embodiments may include some or all of the following features: The method further includes receiving glucose and insulin data for the patient before assessing glycemic risk and quantifying the daily insulin relationship. The glycemic risk is a quantification of current and future risk of hyperglycemia and / or hypoglycemia. Assessing glycemic risk uses at least one of prediction and state estimation. The glycemic risk is assessed in terms of at least one of sample mean, sample variance, time in range, episodes of high / low BG, hypoglycemic risk, hyperglycemic risk, and overall risk. The method further includes generating a risk profile indicating the quantified assessment of glycemic risk. The daily insulin aspect includes at least one of daily total insulin, daily total basal, or daily total bolus. The method further includes identifying a relationship pattern based on the daily insulin aspect for each day over a series of days. Quantifying the daily insulin relationship based on the insulin data further includes calculating at least one of a ratio and a percentage of one aspect of daily insulin to another aspect. The method further includes removing outlier data from at least one of the glucose data and the insulin data before at least one of assessing glycemic risk and quantifying the daily insulin relationship. Determining a recommendation is performed when the daily insulin pattern is outside of a target range, the recommendation being based on the glycemic risk. Determining a recommendation is performed when the daily insulin pattern is outside of a target range and confirmed based on the glycemic risk, the recommendation being based on the amount by which the daily insulin pattern is out of range and at least one of a quantitative assessment of the risk and a qualitative assessment of the risk. Determining a recommendation is performed when the daily insulin pattern is within a target range and the glycemic risk does not meet at least one criterion. The change includes an increase or decrease in the amount of at least one of basal insulin, bolus insulin, and total daily insulin. The recommendation is in the form of a report, command, or signal or instruction to an insulin delivery system or a therapy optimization algorithm.

[0200] In one embodiment, the system includes at least one processor and a non-transitory computer readable medium that, when executed by the at least one processor, causes the system to assess glycemic risk based on glucose data of the patient, where the glucose data includes continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and where the glycemic risk includes at least one of high glycemic risk and low glycemic risk; and quantify a daily insulin relationship based on the insulin data, where quantifying the daily insulin relationship based on the insulin data for each day over the period. and comparing the calculated aspects over the period of time, wherein the insulin data includes basal insulin data and bolus insulin data, the basal insulin data and bolus insulin data received for the patient over the period of time; quantifying and determining a recommendation for one or more aspects of the patient's daily insulin based on the target range and the quantification of the glycemic risk and daily insulin relationship, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin; and outputting the recommendation to a diabetes management system.

[0201] Embodiments may include some or all of the following features: The computer-readable medium further includes instructions that, when executed by at least one processor, cause the system to receive glucose and insulin data for the patient prior to assessing glycemic risk and quantifying daily insulin relationships. The glycemic risk is a quantification of current and future risk of hyperglycemia and / or hypoglycemia. Assessing glycemic risk uses at least one of prediction and state estimation. The glycemic risk is assessed in terms of at least one of sample mean, sample variance, time in range, episodes of high / low BG, hypoglycemic risk, hyperglycemic risk, and overall risk. The computer-readable medium further includes instructions that, when executed by the at least one processor, cause the system to generate a risk profile indicative of the quantified assessment of glycemic risk. The daily insulin aspect includes at least one of daily total insulin, daily total basal, or daily total bolus. The computer-readable medium further includes instructions that, when executed by at least one processor, cause the system to identify a relationship pattern based on daily insulin aspects for each day over a series of days. Quantifying the daily insulin relationship based on the insulin data further includes calculating at least one of a ratio and a percentage of one aspect of daily insulin to another aspect. The computer-readable medium further includes instructions that, when executed by the at least one processor, cause the system to remove outlier data from at least one of the glucose data and the insulin data prior to at least one of assessing glycemic risk and quantifying the daily insulin relationship. Determining a recommendation is performed when the daily insulin pattern is outside of a target range, the recommendation being based on the glycemic risk. Determining a recommendation is performed when the daily insulin pattern is outside of a target range and confirmed based on the glycemic risk, the recommendation being based on at least one of the amount the daily insulin pattern is out of range and a quantitative assessment of the risk and a qualitative assessment of the risk.Determining a recommendation is performed when the daily insulin pattern is within a target range and when the glycemic risk does not meet at least one criterion. The change includes an increase or decrease in the amount of at least one of basal insulin, bolus insulin, and total daily insulin. The recommendation is in the form of a report, command, or signal or instruction to the insulin delivery system or a therapy optimization algorithm.

[0202] In one embodiment, the system includes a glycemic risk assesser configured to assess glycemic risk based on glucose data of the patient, where the glucose data includes continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and the glycemic risk includes at least one of a high glycemic risk and a low glycemic risk; and an insulin relationship quantifier configured to quantify a daily insulin relationship based on the insulin data, where quantifying the daily insulin relationship based on the insulin data includes quantifying a daily insulin relationship for each day over the period of time. and an insulin recommender configured to determine a recommendation for one or more aspects of the patient's daily insulin based on the quantification of the target range and glycemic risk and daily insulin relationship, and output the recommendation to the diabetes management system, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin.

[0203] Embodiments may include some or all of the following features: The glycemic risk assessor is further configured to receive glucose and insulin data for the patient prior to assessing glycemic risk and quantifying the daily insulin relationship. The glycemic risk is a quantification of current and future risk of hyperglycemia and / or hypoglycemia. Assessing glycemic risk uses at least one of prediction and state estimation. The glycemic risk is assessed in terms of at least one of sample mean, sample variance, time in range, episodes of high / low BG, hypoglycemic risk, hyperglycemic risk, and overall risk. The insulin relationship quantifier or insulin recommender is further configured to generate a risk profile indicative of the quantified assessment of glycemic risk. The daily insulin profile includes at least one of daily total insulin, daily total basal, or daily total bolus. The insulin relationship quantifier is further configured to identify a relationship pattern based on the daily insulin profile for each day over a series of days. Quantifying the daily insulin relationship based on the insulin data further includes calculating at least one of a ratio and a percentage of one aspect of the daily insulin to another aspect. The glycemic risk assessor is further configured to remove outlier data from at least one of the glucose data and the insulin data prior to at least one of assessing the glycemic risk and quantifying the daily insulin relationship. Determining a recommendation is performed when the daily insulin pattern is outside of a target range, the recommendation being based on the glycemic risk. Determining a recommendation is performed when the daily insulin pattern is outside of a target range and confirmed based on the glycemic risk, the recommendation being based on at least one of the amount the daily insulin pattern is out of range and a quantitative assessment of the risk and a qualitative assessment of the risk. Determining a recommendation is performed when the daily insulin pattern is within a target range and when the glycemic risk does not meet at least one criterion.The change includes an increase or decrease in the amount of at least one of basal insulin, bolus insulin, and total daily insulin. The recommendation is in the form of a report, command, or signal or instruction to the insulin delivery system or therapy optimization algorithm.

[0204] In one embodiment, a method includes identifying outlier data in a daily insulin-related pattern dataset, analyzing the outlier data in the daily insulin-related pattern dataset, removing the outlier data from the daily insulin-related pattern dataset, and communicating the removal of the outlier data to a diabetes management system.

[0205] Implementations may include some or all of the following features: Outlier data includes inaccurate or erroneous data that distorts the pattern analysis; Analyzing the outlier data includes analyzing the dataset to determine whether at least one of a recommendation and an adjustment can be made; The method further includes outputting information related to the outlier data removed from the daily insulin-related pattern dataset.

[0206] In one embodiment, a system comprises at least one processor and a non-transitory computer-readable medium comprising instructions that, when executed by the at least one processor, cause the system to identify outlier data in a daily insulin-related pattern dataset, analyze the outlier data in the daily insulin-related pattern dataset, remove the outlier data from the daily insulin-related pattern dataset, and communicate the removal of the outlier data to a diabetes management system.

[0207] Implementations may include some or all of the following features: outlier data includes inaccurate or erroneous data that distorts the pattern analysis; analyzing the outlier data includes analyzing the dataset to determine whether at least one of a recommendation and an adjustment can be made; and the computer-readable medium further includes instructions that, when executed by the at least one processor, cause the system to output information related to the outlier data removed from the daily insulin-related pattern dataset.

[0208] In one embodiment, the system includes an insulin relationship quantifier configured to identify outlier data in the daily insulin relationship pattern dataset, analyze the outlier data in the daily insulin relationship pattern dataset, and remove the outlier data from the daily insulin relationship pattern dataset, and an insulin recommender configured to communicate the removal of the outlier data to the diabetes management system.

[0209] Implementations may include some or all of the following features: Outlier data includes inaccurate or erroneous data that distorts the pattern analysis; Analyzing the outlier data includes analyzing the dataset to determine whether at least one of a recommendation and an adjustment can be made; The insulin recommender is further configured to output information related to the outlier data removed from the daily insulin-related pattern dataset.

[0210] In one embodiment, a method includes identifying variability in a daily insulin-related pattern dataset; analyzing the variability, including analyzing data that falls at least one of above a target range, within a target range, or below a target range; and making adjustments to the dataset based on the analyzing.

[0211] Embodiments may include some or all of the following features: Identifying variability includes at least one of analyzing individual data points or evaluating mean or standard deviation against one or more criteria; Identifying variability includes evaluating a superset of the data to identify one or more subsets of data associated with different daily insulin patterns; Making adjustments includes at least one of adjusting the definition of the data and splitting the data into multiple separate data sets or patterns.

[0212] In one embodiment, the system comprises at least one processor and a non-transitory computer-readable medium comprising instructions that, when executed by the at least one processor, cause the system to: identify variability in a daily insulin-related pattern dataset; analyze the variability, where the variability includes analyzing data that falls at least one of above a target range, within a target range, or below a target range; and make adjustments to the dataset based on the analyzing.

[0213] Embodiments may include some or all of the following features: Identifying variability includes at least one of analyzing individual data points or evaluating mean or standard deviation against one or more criteria; Identifying variability includes evaluating a superset of the data to identify one or more subsets of data associated with different daily insulin patterns; Making adjustments includes at least one of adjusting the definition of the data and splitting the data into multiple separate data sets or patterns.

[0214] In one embodiment, the system comprises at least one insulin-related quantifier or insulin recommender configured to: identify variability in a daily insulin-related pattern dataset; analyze the variability, where the variability includes analyzing data that falls at least one of above a target range, within a target range, or below a target range; and make adjustments to the dataset based on the analyzing.

[0215] Embodiments may include some or all of the following features: Identifying variability includes at least one of analyzing individual data points or evaluating mean or standard deviation against one or more criteria; Identifying variability includes evaluating a superset of the data to identify one or more subsets of data associated with different daily insulin patterns; Making adjustments includes at least one of adjusting the definition of the data and splitting the data into multiple separate data sets or patterns.

[0216] It should be understood that the various techniques described herein may be implemented in connection with hardware or software components or, where appropriate, with a combination of both. Exemplary types of hardware components that may be used include Field-Programmable Gate Arrays (FPGAs), Application-Specific Integrated Circuits (ASICs), Application-Specific Standard Products (ASSPs), System-on-a-Chip systems (SOCs), Complex Programmable Logic Devices (CPLDs), etc. The methods and apparatus of the presently disclosed subject matter, or certain aspects or portions thereof, may take the form of program code (i.e., instructions) embodied in a tangible medium, such as a floppy diskette, CD-ROM, hard drive, or any other machine-readable storage medium; when the program code is loaded into and executed by a machine, such as a computer, the machine becomes an apparatus for practicing the presently disclosed subject matter.

[0217] Although example implementations may refer to utilizing aspects of the presently disclosed subject matter in the context of one or more stand-alone computer systems, the subject matter is not so limited and, rather, may be implemented in connection with any computing environment, such as a network or distributed computing environment. Furthermore, aspects of the subject matter disclosed herein may be implemented in or across multiple processing chips or devices, as well as stored across multiple devices. Such devices may include, for example, personal computers, network servers, and handheld devices.

[0218] Although the systems and techniques have been described in language specific to structural features and / or methodological acts, it should be understood that the systems and techniques defined in the appended claims are not necessarily limited to the specific features or acts described. Rather, the specific features and acts described above are disclosed as example forms of implementing the claims.

Claims

1. A method executed by at least one processor, comprising: assessing a glycemic risk based on the patient's glucose data, the glucose data including continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, the glycemic risk including at least one of a high glycemic risk and a low glycemic risk; quantifying a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, wherein the insulin data comprises basal insulin data and bolus insulin data, and the basal insulin data and the bolus insulin data are received for the patient over the period of time; determining a recommendation for one or more aspects of the patient's daily insulin based on a target range for a basal / bolus ratio and the quantification of the glycemic risk and the daily insulin relationship, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin; and outputting the recommendation to a diabetes management system.

2. 10. The method of claim 1, further comprising receiving the glucose data and the insulin data for the patient prior to assessing the glycemic risk and quantifying the daily insulin relationship.

3. 3. The method of claim 1 or 2, wherein the glycemic risk is a quantified current and future risk of hyperglycemia and / or hypoglycemia.

4. The method of any one of claims 1 to 3, wherein assessing the glycemic risk uses at least one of hyperglycemia and / or hypoglycemia prediction and state estimation.

5. 5. The method of any one of claims 1 to 4, wherein the glycemic risk is assessed in terms of at least one of sample mean, sample variance, time in range, high / low BG (blood glucose) episodes, hypoglycemic risk, hyperglycemic risk, and overall risk.

6. 6. The method of any one of claims 1 to 5, further comprising generating a risk profile indicating a quantified assessment of glycemic risk.

7. 7. The method of any one of claims 1 to 6, wherein the daily insulin profile comprises at least one of total daily insulin, total daily basal, or total daily bolus.

8. 8. The method of claim 1, further comprising identifying a relationship pattern based on the daily insulin profile for each day over a series of days.

9. 9. The method of claim 1, wherein quantifying the daily insulin relationship based on insulin data further comprises calculating at least one of a ratio and a percentage of one aspect of daily insulin to another aspect.

10. 10. The method of claim 1, further comprising removing outlier data from at least one of the glucose data and the insulin data prior to at least one of assessing the glycemic risk and quantifying the daily insulin relationship.

11. 11. The method of any one of claims 1 to 10, wherein determining the recommendation is performed when a daily insulin pattern is outside the target range, and the recommendation is based on the glycemic risk.

12. 12. The method of any one of claims 1 to 11, wherein determining the recommendation is performed when a daily insulin pattern is outside the target range and is ascertained based on the glycemic risk, and the recommendation is based on the amount by which the daily insulin pattern is outside the range and at least one of a quantitative assessment of risk and a qualitative assessment of risk.

13. 13. The method of any one of claims 1 to 12, wherein determining the recommendation is performed when the daily insulin pattern is within the target range and when the glycemic risk does not meet at least one criterion.

14. 14. The method of any one of claims 1 to 13, wherein the change comprises an increase or decrease in the amount of at least one of basal insulin, bolus insulin, and total daily insulin.

15. The method of any one of claims 1 to 14, wherein the recommendation is in the form of a report, command, or signal or instruction to an insulin delivery system or a therapy optimization algorithm.

16. 1. A system comprising: at least one processor; A non-transitory computer-readable medium that, when executed by the at least one processor, provides the system with: assessing a glycemic risk based on the patient's glucose data, the glucose data including continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, the glycemic risk including at least one of a high glycemic risk and a low glycemic risk; quantifying a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, wherein the insulin data comprises basal insulin data and bolus insulin data, and the basal insulin data and the bolus insulin data are received for the patient over the period of time; determining a recommendation for one or more aspects of the patient's daily insulin based on a target range for a basal / bolus ratio and the quantification of the glycemic risk and the daily insulin relationship, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin; outputting the recommendation to a diabetes management system.

17. 17. The system of claim 16, wherein the computer-readable medium further comprises instructions that, when executed by the at least one processor, cause the system to receive the glucose data and the insulin data for the patient prior to assessing the glycemic risk and quantifying the daily insulin relationship.

18. 18. The system of claim 16 or 17, wherein the glycemic risk is a quantified current and future risk of hyperglycemia and / or hypoglycemia.

19. The system of any one of claims 16 to 18, wherein assessing the glycemic risk uses at least one of hyperglycemia and / or hypoglycemia prediction and state estimation.

20. 20. The system of any one of claims 16 to 19, wherein the glycemic risk is assessed in terms of at least one of sample mean, sample variance, time in range, high / low BG (blood glucose) episodes, hypoglycemic risk, hyperglycemic risk, and overall risk.

21. 21. The system of any one of claims 16-20, wherein the computer-readable medium further comprises instructions that, when executed by the at least one processor, cause the system to generate a risk profile indicative of a quantified assessment of glycemic risk.

22. 22. The system of any one of claims 16 to 21, wherein the daily insulin aspect comprises at least one of total daily insulin, total daily basal, or total daily bolus.

23. 23. The system of any one of claims 16-22, wherein the computer-readable medium further comprises instructions that, when executed by the at least one processor, cause the system to identify relationship patterns based on the daily insulin profile for each day over a series of days.

24. 24. The system of claim 16, wherein quantifying the daily insulin relationship based on insulin data further comprises calculating at least one of a ratio and a percentage of one aspect of daily insulin to another aspect.

25. 25. The system of any one of claims 16-24, wherein the computer-readable medium further comprises instructions that, when executed by the at least one processor, cause the system to remove outlier data from at least one of the glucose data and the insulin data prior to at least one of assessing the glycemic risk and quantifying the daily insulin relationship.

26. 26. The system of any one of claims 16 to 25, wherein determining the recommendation is performed when the daily insulin pattern is outside the target range, and the recommendation is based on the glycemic risk.

27. 27. The system of claim 16, wherein determining the recommendation is performed when a daily insulin pattern is outside the target range and is ascertained based on the glycemic risk, and the recommendation is based on the amount by which the daily insulin pattern is outside the range and at least one of a quantitative assessment of risk and a qualitative assessment of risk.

28. 28. The system of any one of claims 16 to 27, wherein determining the recommendation is performed when the daily insulin pattern is within the target range and when the glycemic risk does not meet at least one criterion.

29. 29. The system of any one of claims 16 to 28, wherein the change comprises an increase or decrease in the amount of at least one of basal insulin, bolus insulin, and total daily insulin.

30. The system of any one of claims 16 to 29, wherein the recommendation is in the form of a report, command, or signal or instruction to an insulin delivery system or a therapy optimization algorithm.

31. 1. A system comprising: a glycemic risk assessor configured to assess a glycemic risk based on glucose data of a patient, the glucose data comprising continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and the glycemic risk comprising at least one of a high glycemic risk and a low glycemic risk; an insulin relationship quantifier configured to quantify a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, wherein the insulin data comprises basal insulin data and bolus insulin data, and the basal insulin data and the bolus insulin data are received for the patient over the period of time; an insulin recommender configured to determine a recommendation for one or more aspects of the patient's daily insulin based on a target range for the basal / bolus ratio and the quantification of the glycemic risk and the daily insulin relationship, and to output the recommendation to a diabetes management system, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin.

32. 32. The system of claim 31, wherein the glycemic risk assessor is further configured to receive the glucose data and the insulin data for the patient before assessing the glycemic risk and quantifying the daily insulin relationship.

33. 33. The system of claim 31 or 32, wherein the glycemic risk is a quantified current and future risk of hyperglycemia and / or hypoglycemia.

34. 34. The system of any one of claims 31 to 33, wherein assessing the glycemic risk uses at least one of hyperglycemia and / or hypoglycemia prediction and state estimation.

35. 35. The system of any one of claims 31 to 34, wherein the glycemic risk is assessed in terms of at least one of sample mean, sample variance, time in range, high / low BG (blood glucose) episodes, hypoglycemic risk, hyperglycemic risk, and overall risk.

36. 36. The system of any one of claims 31 to 35, wherein the insulin relationship quantifier or the insulin recommender is further configured to generate a risk profile indicating a quantified assessment of glycemic risk.

37. 37. The system of any one of claims 31 to 36, wherein the daily insulin aspect comprises at least one of total daily insulin, total daily basal, or total daily bolus.

38. 38. The system of any one of claims 31-37, wherein the insulin relationship quantifier is further configured to identify a relationship pattern based on the daily insulin profile for each day over a series of days.

39. 39. The system of any one of claims 31-38, wherein quantifying the daily insulin relationship based on insulin data further comprises calculating at least one of a ratio and a percentage of one aspect of daily insulin to another aspect.

40. 40. The system of any one of claims 31-39, wherein the glycemic risk assessor is further configured to remove outlier data from at least one of the glucose data and the insulin data prior to at least one of assessing the glycemic risk and quantifying the daily insulin relationship.

41. 41. The system of any one of claims 31 to 40, wherein determining the recommendation is performed when the daily insulin pattern is outside the target range, and the recommendation is based on the glycemic risk.

42. 42. The system of any one of claims 31 to 41, wherein determining the recommendation is performed when a daily insulin pattern is outside the target range and is ascertained based on the glycemic risk, and the recommendation is based on the amount by which the daily insulin pattern is outside the range and at least one of a quantitative assessment of risk and a qualitative assessment of risk.

43. 43. The system of any one of claims 31 to 42, wherein determining the recommendation is performed when the daily insulin pattern is within the target range and when the glycemic risk does not meet at least one criterion.

44. 44. The system of any one of claims 31 to 43, wherein the change comprises an increase or decrease in the amount of at least one of basal insulin, bolus insulin, and total daily insulin.

45. 45. The system of any one of claims 31 to 44, wherein the recommendation is in the form of a report, command, or signal or instruction to an insulin delivery system or a therapy optimization algorithm.

46. ​​A method executed by at least one processor, comprising: Identifying outlier data in the daily insulin-related pattern dataset; Analyzing outlier data in the daily insulin-related pattern dataset; removing the outlier data from the daily insulin-related pattern dataset; communicating the removal of the outlier data to a diabetes management system; assessing a glycemic risk based on the patient's glucose data, the glucose data including continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, the glycemic risk including at least one of a high glycemic risk and a low glycemic risk; quantifying a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, wherein the insulin data comprises basal insulin data and bolus insulin data, and the basal insulin data and the bolus insulin data are received for the patient over the period of time; determining a recommendation for one or more aspects of the patient's daily insulin based on a target range for a basal / bolus ratio and the quantification of the glycemic risk and the daily insulin relationship, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin; outputting the recommendation to the diabetes management system.

47. 47. The method of claim 46, wherein the outlier data comprises inaccurate or erroneous data that distorts pattern analysis.

48. 48. The method of claim 46 or 47, wherein analyzing the outlier data comprises analyzing the data set to determine whether at least one of a recommendation and an adjustment can be made.

49. 49. The method of any one of claims 46-48, further comprising outputting information related to the outlier data removed from the daily insulin-related pattern dataset.

50. 1. A system comprising: at least one processor; A non-transitory computer-readable medium that, when executed by the at least one processor, provides the system with: Identifying outlier data in the daily insulin-related pattern dataset; Analyzing outlier data in the daily insulin-related pattern dataset; removing the outlier data from the daily insulin-related pattern dataset; communicating the removal of the outlier data to a diabetes management system; assessing a glycemic risk based on the patient's glucose data, the glucose data including continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, the glycemic risk including at least one of a high glycemic risk and a low glycemic risk; quantifying a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, wherein the insulin data comprises basal insulin data and bolus insulin data, and the basal insulin data and the bolus insulin data are received for the patient over the period of time; determining a recommendation for one or more aspects of the patient's daily insulin based on a target range for a basal / bolus ratio and the quantification of the glycemic risk and the daily insulin relationship, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin; and outputting the recommendation to the diabetes management system.

51. 51. The system of claim 50, wherein the outlier data comprises inaccurate or erroneous data that distorts pattern analysis.

52. 52. The system of claim 50 or 51, wherein analyzing the outlier data includes analyzing the data set to determine whether at least one of a recommendation and an adjustment can be made.

53. 53. The system of any one of claims 50-52, wherein the computer-readable medium further comprises instructions that, when executed by the at least one processor, cause the system to output information related to the outlier data removed from the daily insulin-related pattern dataset.

54. 1. A system comprising: a glycemic risk assessor configured to assess a glycemic risk based on glucose data of a patient, the glucose data comprising continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and the glycemic risk comprising at least one of a high glycemic risk and a low glycemic risk; 1. An insulin-related quantifier comprising: Identifying outlier data in the daily insulin-related pattern dataset; Analyzing outlier data in the daily insulin-related pattern dataset; removing the outlier data from the daily insulin-related pattern dataset; an insulin relationship quantifier configured to quantify a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, wherein the insulin data comprises basal insulin data and bolus insulin data, and the basal insulin data and the bolus insulin data are received for the patient over the period of time; an insulin recommender configured to communicate the removal of the outlier data to a diabetes management system, and configured to determine a recommendation for one or more aspects of the patient's daily insulin based on a target range for basal / bolus ratio and the quantification of the glycemic risk and the daily insulin relationship, and output the recommendation to the diabetes management system, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin.

55. 55. The system of claim 54, wherein the outlier data comprises inaccurate or erroneous data that distorts pattern analysis.

56. 56. The system of claim 54 or 55, wherein analyzing the outlier data comprises analyzing the data set to determine whether at least one of a recommendation and an adjustment can be made.

57. 57. The system of any one of claims 54-56, wherein the insulin recommender is further configured to output information related to the outlier data removed from the daily insulin-related pattern dataset.

58. A method executed by at least one processor, comprising: assessing a glycemic risk based on the patient's glucose data, the glucose data including continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, the glycemic risk including at least one of a high glycemic risk and a low glycemic risk; quantifying a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, wherein the insulin data comprises basal insulin data and bolus insulin data, and the basal insulin data and the bolus insulin data are received for the patient over the period of time; Identifying variability in the daily insulin-related pattern dataset; analyzing the variability, including analyzing data that falls at least one of above, within, or below a target range for the basal / bolus ratio; making adjustments to the data set based on said analyzing; determining a recommendation for one or more aspects of the patient's daily insulin based on the target range and the quantification of the glycemic risk and the daily insulin relationship, the recommendation including a change in at least one of basal insulin, bolus insulin, and daily total insulin; and outputting the recommendation to a diabetes management system.

59. 59. The method of claim 58, wherein determining the variability comprises at least one of analyzing individual data points or assessing the mean or standard deviation against one or more criteria.

60. 60. The method of claim 58 or 59, wherein identifying the variability comprises evaluating a superset of data to identify one or more subsets of data associated with different daily insulin patterns.

61. 61. The method of any one of claims 58 to 60, wherein adjusting comprises at least one of adjusting a definition of the data and splitting the data into a plurality of separate data sets or data patterns.

62. 1. A system comprising: at least one processor; a non-transitory computer-readable medium that, when executed by the at least one processor, provides the system with: assessing a glycemic risk based on the patient's glucose data, the glucose data including continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, the glycemic risk including at least one of a high glycemic risk and a low glycemic risk; quantifying a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, wherein the insulin data comprises basal insulin data and bolus insulin data, and the basal insulin data and the bolus insulin data are received for the patient over the period of time; Identifying variability in the daily insulin-related pattern dataset; analyzing the variability, including analyzing data that falls at least one of above, within, or below a target range for the basal / bolus ratio; making adjustments to the data set based on said analyzing; determining a recommendation for one or more aspects of the patient's daily insulin based on the target range and the quantification of the glycemic risk and the daily insulin relationship, the recommendation including a change in at least one of basal insulin, bolus insulin, and daily total insulin; outputting the recommendation to a diabetes management system.

63. 63. The system of claim 62, wherein identifying the variability comprises at least one of analyzing individual data points or evaluating the mean or standard deviation against one or more criteria.

64. 64. The system of claim 62 or 63, wherein identifying the variability comprises evaluating a superset of data to identify one or more subsets of data associated with different daily insulin patterns.

65. 65. The system of any one of claims 62 to 64, wherein adjusting comprises at least one of adjusting a definition of the data and splitting the data into a plurality of separate data sets or data patterns.

66. 1. A system comprising: a glycemic risk assessor configured to assess a glycemic risk based on glucose data of a patient, the glucose data comprising continuous glucose monitoring (CGM) data or flash glucose monitoring (FGM) data received for the patient over a period of time, and the glycemic risk comprising at least one of a high glycemic risk and a low glycemic risk; An insulin-related quantifier or insulin recommender, comprising:

1. An insulin relationship quantifier configured to quantify a daily insulin relationship based on insulin data, wherein quantifying the daily insulin relationship based on the insulin data comprises calculating a plurality of aspects of daily insulin for each day over the period of time and comparing the calculated aspects over the period of time, the insulin data comprising basal insulin data and bolus insulin data, the basal insulin data and the bolus insulin data being received for the patient over the period of time; Identifying variability in the daily insulin-related pattern dataset; analyzing the variability, including analyzing data that falls at least one of above, within, or below a target range for the basal / bolus ratio; making adjustments to the dataset based on the analyzing; The system includes an insulin recommender configured to determine a recommendation for one or more aspects of the patient's daily insulin based on the target range and the quantification of the glycemic risk and the daily insulin relationship, and output the recommendation to a diabetes management system, wherein the recommendation includes a change in at least one of basal insulin, bolus insulin, and daily total insulin.

67. 67. The system of claim 66, wherein identifying the variability comprises at least one of analyzing individual data points or evaluating the mean or standard deviation against one or more criteria.

68. 68. The system of claim 66 or 67, wherein identifying the variability comprises evaluating a superset of data to identify one or more subsets of data associated with different daily insulin patterns.

69. 69. The system of any one of claims 66 to 68, wherein performing the adjustment comprises at least one of adjusting a definition of the data and splitting the data into a plurality of separate data sets or data patterns.

Images